This event has ended. Create your own event → Check it out
This event has ended. Create your own
View analytic
Thursday, September 21 • 9:00am - 10:30am
SDDN Programming: Scientific Presentations
Feedback form is now closed.
This year the SDDN / SLAS 2017 meeting has the theme "Case Studies in Drug Discovery and Development", and it will showcase several success stories, from academia, biotech, and pharma; opportunities, challenges, solutions and lessons learned will be highlighted. 

This programme is graciously sponsored by Promega

Welcome and opening remarks will be followed by three (3), 30-minute presentations

José Antonio Enríquez, CNIC 

Here we will discuss on the partnership between CNIC/INOPHARMA on the definition of a new target for heart failure (HF). We present three different models of HF in mice: tachycardiomyopathy, HF with preserved left ventricular (LV) ejection fraction, and LV myocardial ischemia and hypertrophy. Regardless of whether LVEF is preserved or reduced, our results indicate that the three models share common molecular features: an increase in mitochondrial ROS, followed by ultrastructural alterations in the mitochondrial cristae and loss of mitoc­­hondrial integrity that lead to cardiomyocyte death. We show that the ablation of the mitochondrial protease OMA1 averts cardiomyocyte death in all three experimental HF models and thus plays a direct role in cardiomyocyte protection. This finding identifies OMA1 as a potential target for preventing the progression of myocardial damage in HF associated to a variety of etiologies. 

Drug Discovery of allosteric inhibitors: the experience from Allinky
Miguel Vega, Allinky 

Allinky Biopharma is a biotech company-associated to academia-that focuses its activities on the discovery and development of small molecules to treat chronic inflammatory conditions, age-related degenerative diseases and cancer.

Bridging early academic research & clinical development on polypeptide-based nanomedicines
María Jesús Vicent, Polypeptide Therapeutic Solutions

PTS is a spin-off company from the Polymer Therapeutics Lab. headed by Dr Vicent at Centro de Investigación Príncipe Felipe (CIPF, Valencia, Spain) that devotes considerable efforts in R&D projects.  It was born trying to fill the gap between the research at the benchside and the big pharma within a very promising field polypeptide-based nanomedicines.

PTS aim to: a) the production and commercialisation of polypeptide-based systems (hydrogel and drug delivery systems) with structural & chemical diversity and functionality, but also well-defined architecture in terms of Mw and low polydispersities; b) development of polypeptide-based drug delivery systems for topical applications.

Very recently PTS has invested a large amount of human and economic resources to implement: i) a quality system following FDA and ICH guidelines for the manufacturing of pharmaceutical and cosmetic ingredients under GMP-compliant (not certified) quality grade; ii) Instrumental techniques and analytical developments to cover all the characterization required by ICH guideline Q6ASpecifications and iii) Up-scale manufacturing allowing to produce the polypeptides at Kg scale.

We have developed a cross-linked biopolymer hydrogel platform capable to enhance the permeation of actives to target skin layers. Moreover, the production under Good Manufacturing Process (GMPs) for cosmetic and therapeutic products for human beings has been the milestone for PTS along 2017 and will continue in 2018, for which PTS has built a structure to provide feasible translation from research products to clinical development and market.  

avatar for José Antonio Enríquez

José Antonio Enríquez

Dr. José Antonio Enríquez, has a wide experience in biogenesis and pathology of mtDNA. He obtained his PhD studying the expression of mtDNA in the departamento de Bioquímica (Universidad de Zaragoza) and supported by a D.G.A. fellowship. In 1992, started his post-doctoral training in CALTECH, under... Read More →
avatar for Miguel Vega

Miguel Vega

Miguel has a broad background in engineering and management, with specific training and expertise in molecular and cell biology, chemical and biochemical synthesis, industrial processing as well project design and implementation. For the last 20 years he has been involved in proj... Read More →
avatar for María Jesús Vicent

María Jesús Vicent

Team Leader (Polymer Therapeutics Laboratory-Scree, Centro de Investigación Príncipe Felipe
Dr. María J. Vicent received her Ph.D. degree in 2001 in chemistry on solid supports from University Jaume I after several scientific stays in Prof. Fréchet’s lab. at University California, Berkeley (USA). Then, she moved to more biomedically oriented research, initially with a Spanish company Instituto Biomar SA., and subsequently at the Centre for Polymer Therapeutics with Prof. R. Duncan after the award of a Marie Curie Postdoctoral Fellowship in 2002. In 2004... Read More →

Thursday September 21, 2017 9:00am - 10:30am
Rosales I Courtyard by Marriot Madrid Princesa Hotel